Saccovid (efprezimod alfa)

Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning for hematologic malignancies often develop acute graft-vs-host disease (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with methotrexate. The multidose regimen of CD24Fc was well tolerated with no DLTs and was associated with high rates of severe acute GVHD-free survival after myeloablative MUD HSCT. This trial was registered at ClinicalTrials.gov as NCT02663622.

This study illustrates that the combination of Myc suppressed whole tumor cell vaccination with checkpoint inhibitors is an effective therapy, but occult immune infiltrates are induced in several organ systems in a mouse neuroblastoma model. The systemic administration of CD24-Fc suppresses autoimmune tissue responses, but appropriate timing of administration is critical for maintaining efficacy of the therapeutic vaccine.

P1/2, N=3, Terminated, Tianhong Li | N=78 --> 3 | Active, not recruiting --> Terminated; Terminated early by the Sponsor due to the sponsor change.

P3, N=11, Terminated, OncoImmune, Inc. | Active, not recruiting --> Terminated; Business Reasons

P3, N=11, Active, not recruiting, OncoImmune, Inc. | N=180 --> 11

P1/2, N=78, Active, not recruiting, Tianhong Li | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Feb 2022 | Trial primary completion date: Oct 2022 --> Feb 2021

P3, N=11, Active, not recruiting, Merck Sharp & Dohme Corp.

P2, N=44, Completed, OncoImmune, Inc. | Active, not recruiting --> Completed

P3, N=180, Active, not recruiting, OncoImmune, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2021 | Trial primary completion date: Aug 2023 --> Nov 2021

P2, N=44, Active, not recruiting, OncoImmune, Inc. | Completed --> Active, not recruiting | Trial completion date: Jan 2021 --> May 2021

P3, N=180, Recruiting, OncoImmune, Inc. | Trial completion date: Dec 2024 --> Feb 2024 | Trial primary completion date: Dec 2023 --> Aug 2023

P2, N=44, Completed, OncoImmune, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2021 --> Jan 2021

P2, N=44, Active, not recruiting, OncoImmune, Inc. | Trial completion date: Dec 2020 --> Apr 2021

P1/2, N=78, Recruiting, Tianhong Li | Not yet recruiting --> Recruiting

P3, N=180, Recruiting, OncoImmune, Inc. | Not yet recruiting --> Recruiting

P1/2, N=78, Not yet recruiting, Tianhong Li